Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD

January 26, 2017
Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Speaking at the 2017 Biotech Showcase, Dr. Jill Milne, co-founder, president and CEO of Catabasis, describes to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, the company’s ambitions to pursue a pivotal Phase III trial this year.
Previous Video
Biotech Showcase™ 2017: PatientsLikeMe takes a holistic route to meet patient needs
Biotech Showcase™ 2017: PatientsLikeMe takes a holistic route to meet patient needs

Jamie Heywood, co-founder and chairman of PatientsLikeMe spoke to Mike Ward, Informa Pharma Intelligence’s ...

Next Video
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry

With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-...